SHARE
Ophthalmic Drugs Market

Ophthalmic Drugs Market Forecasts to 2028 – Global Analysis By Technology (Drug Delivery, Gene Therapy, Biologics, Small Molecule, Cell Therapy), End User (Specialty Clinics, Hospitals, Pharmacy), and By Geography

4.5 (69 reviews)
Published: June 2021 ID: SMRC20572
4.5 (69 reviews)
Published: June 2021 ID: SMRC20572

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Ophthalmic Drugs market is accounted for $36.70 billion in 2020 and is expected to reach $70.49 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Some of the key factors propelling the market growth include rising R&D pertaining to the development of novel drugs, increasing focus on developing combination therapies, rising advancements in technologies, favorable reimbursement policies, increasing accessibility for healthcare facilities, and increasing incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections. However, loss of patent protection for popular drugs is restraining the market growth.


Ophthalmic drugs are used to treat eye infection and various types of eye conditions. These are used in the treatment of dry eye, age-related macular degeneration, diabetic retinopathy, and other eye disorders. Ophthalmic diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, retinal vein occlusion (RVO), and myopic choroidal neovascularization, are potential threats to an individual’s sight. Ophthalmic drug forms have been one of the most important and widely developed areas of pharmaceutical technology over the few years.

By indication, the dry eye segment is anticipated to grow at the significant rate during the forecast period, increased dry eye cases among the peoples. Dry eye disease (DED) is a multifactorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to ageing, and hence, it remains an under-researched condition in the low- and middle-income countries. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the ageing population and the adoption of modern lifestyle.

On the basis of geography, the Asia Pacific is estimated to be the fastest-growing region in the market over the forecast period, due to increasing burden of ophthalmic disorders and rising consumer awareness. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the clinical and experimental vision and eye research, India, 2018. Moreover, increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth.

Some of the key players in Ophthalmic Drugs Market include Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.

Report Coverage

Details

Published Year:

2021

Estimated Market Size in 2020:

USD 36.70 billion

Estimated Period:

2020

Compound Annual Growth Rate (CAGR)  from 2020 to 2028:

8.5%

Predicted 2028 Value:

USD 70.49 billion

Forecast Years:

2021-2028

Tables, Graphs & Figures

478

Chapters Covered:

Type, Technology, Drug Variation, Indication, Distribution Channel, Route of Administration, Dosage Form, Delivery Type, Therapeutic Class, End User

Core Drivers and Opportunities:

  • Increasing incidence and prevalence of eye-related disorders
  • Increasing focus on developing combination therapies
  • Multi-vendor device support and industry compliance

Restraining Factors & Market Threats:

  • Loss of patent protection for popular drugs
  • Lack of health insurance in the developing countries


Types Covered:
• Over-the-Counter Drugs
• Prescription Drugs

Technologies Covered:
• Drug Delivery
• Gene Therapy
• Biologics
• Small Molecule
• Cell Therapy

Drug Variations Covered:
• Generic Drugs
• Branded Drugs

Indications Covered:
• Glaucoma
• Dry Eye
• Cataract
• Retinal Disorders
• Uveitis
• Eye Infection/Inflammation/Eye Allergy
• Allergic Conjunctivitis
• Age-Related Macular Degeneration (AMD)
• Diabetic Eye Disease
• Other Indications

Distribution Channels Covered:
• Drug Stores
• Hospital Pharmacies
• Online Pharmacies
• Eye Health Clinics
• Retail Pharmacies/Independent Pharmacies

Route of Administrations Covered:
• Systemic
• Local Ocular
• Topical
• Oral
• Parenteral

Dosage Forms Covered:
• Solid Ophthalmic Drug Forms
• Liquid Ophthalmic Drug Forms
• Multicompartment Drug Delivery Systems
• Semisolid Ophthalmic Drug Forms

Delivery Types Covered:
• Eye Solutions
• Capsules & Tablets
• Eye Ointment
• Gels
• Eye Drops

Therapeutic Classes Covered:
• Anti-Inflammatory
• Antibiotics
• Anti-Allergy
• Anti-Glaucoma Drugs
• Anti-Angiogenic
• Anti-Infective Drugs
• Anti-Vascular Endothelial Growth Factor (VEGF) Agents
• Retinal Drug
• Other Therapeutic Classes (Cyclosporine)

End Users Covered:
• Specialty Clinics
• Hospitals
• Pharmacy

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain
o Rest of Europe      
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand 
o South Korea              
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2019, 2020, 2021, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Key Questions Answered In The Report

The Global Ophthalmic Drugs Market is majorly driven by increasing awareness regarding eye-related diseases, rising R&D pertaining to the development of novel drugs, increasing focus on developing combination therapies, and rising advancements in technologies.

The dry eye segment is growing at a highest CAGR owing to increased dry eye cases among the people, increasing proportion of the ageing population and the adoption of modern lifestyle.

North America dominated with a significant market share due to the factors such as the presence of excellent healthcare infrastructure and high consumer awareness.

Asia Pacific market is growing at a highest CAGR owing to increasing burden of ophthalmic disorders, increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the region.

Key players in Ophthalmic Drugs Market include Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.

1 Executive Summary       
        
2 Preface     
  
 2.1 Abstract      
 2.2 Stake Holders       
 2.3 Research Scope      
 2.4 Research Methodology      
  2.4.1 Data Mining     
  2.4.2 Data Analysis     
  2.4.3 Data Validation     
  2.4.4 Research Approach     
 2.5 Research Sources      
  2.5.1 Primary Research Sources     
  2.5.2 Secondary Research Sources     
  2.5.3 Assumptions     
        
3 Market Trend Analysis       
 3.1 Introduction      
 3.2 Drivers      
 3.3 Restraints      
 3.4 Opportunities      
 3.5 Threats      
 3.6 Technology Analysis      
 3.7 End User Analysis      
 3.8 Emerging Markets      
 3.9 Impact of Covid-19      
        
4 Porters Five Force Analysis       
 4.1 Bargaining power of suppliers      
 4.2 Bargaining power of buyers      
 4.3 Threat of substitutes      
 4.4 Threat of new entrants      
 4.5 Competitive rivalry      
        
5 Global Ophthalmic Drugs Market, By Type       
 5.1 Introduction      
 5.2 Over-the-Counter Drugs      
 5.3 Prescription Drugs      
        
6 Global Ophthalmic Drugs Market, By Technology       
 6.1 Introduction      
 6.2 Drug Delivery      
 6.3 Gene Therapy      
 6.4 Biologics      
 6.5 Small Molecule      
 6.6 Cell Therapy      
        
7 Global Ophthalmic Drugs Market, By Drug Variation       
 7.1 Introduction       
 7.2 Generic Drugs      
 7.3 Branded Drugs      
        
8 Global Ophthalmic Drugs Market, By Indication       
 8.1 Introduction      
 8.2 Glaucoma      
 8.3 Dry Eye      
 8.4 Cataract      
 8.5 Retinal Disorders      
  8.5.1 Diabetic Retinopathy     
  8.5.2 Macular Degeneration     
   8.5.2.1 Dry Age-Related Macular Degeneration    
   8.5.2.2 Wet Age-Related Macular Degeneration    
 8.6 Uveitis      
 8.7 Eye Infection/Inflammation/Eye Allergy      
 8.8 Allergic Conjunctivitis      
 8.9 Age-Related Macular Degeneration (AMD)      
 8.10 Diabetic Eye Disease      
 8.11 Other Indications      
  8.11.1 Eyelash Hypotrichosis     
  8.11.2 Optic Neuropathy     
        
9 Global Ophthalmic Drugs Market, By Distribution Channel       
 9.1 Introduction      
 9.2 Drug Stores      
 9.3 Hospital Pharmacies      
 9.4 Online Pharmacies      
 9.5 Eye Health Clinics      
 9.6 Retail Pharmacies/Independent Pharmacies      
        
10 Global Ophthalmic Drugs Market, By Route of Administration       
 10.1 Introduction      
 10.2 Systemic      
 10.3 Local Ocular      
  10.3.1 Retrobulbar     
  10.3.2 Subconjunctival     
  10.3.3 Intracameral     
  10.3.4 Intravitreal     
 10.4 Topical      
 10.5 Oral       
 10.6 Parenteral      
        
11 Global Ophthalmic Drugs Market, By Dosage Form       
 11.1 Introduction      
 11.2 Solid Ophthalmic Drug Forms      
 11.3 Liquid Ophthalmic Drug Forms      
 11.4 Multicompartment Drug Delivery Systems       
 11.5 Semisolid Ophthalmic Drug Forms      
        
12 Global Ophthalmic Drugs Market, By Delivery Type       
 12.1 Introduction      
 12.2 Eye Solutions      
 12.3 Capsules & Tablets      
 12.4 Eye Ointment      
 12.5 Gels      
 12.6 Eye Drops      
        
13 Global Ophthalmic Drugs Market, By Therapeutic Class       
 13.1 Introduction      
 13.2 Anti-Inflammatory      
  13.2.1 Steroidal Drugs     
  13.2.2 Non-Steroidal Anti-Inflammatory drugs (NSAIDs)     
 13.3 Antibiotics       
 13.4 Anti-Allergy      
 13.5 Anti-Glaucoma Drugs      
  13.5.1 Prostaglandin Analogs     
  13.5.2 Combined Medication     
  13.5.3 Alpha Agonist     
  13.5.4 Beta-Blockers     
 13.6 Anti-Angiogenic      
 13.7 Anti-Infective Drugs       
  13.7.1 Anti-Fungal Drugs     
  13.7.2 Anti-Bacterial Drugs     
  13.7.3 Anti-Viral Drugs     
 13.8 Anti-Vascular Endothelial Growth Factor (VEGF) Agents      
 13.9 Retinal Drug      
 13.10 Other Therapeutic Classes (Cyclosporine)      
         
14 Global Ophthalmic Drugs Market, By End User       
 14.1 Introduction      
 14.2 Specialty Clinics      
 14.3 Hospitals      
 14.4 Pharmacy      
        
15 Global Ophthalmic Drugs Market, By Geography       
 15.1 Introduction      
 15.2 North America      
  15.2.1 US     
  15.2.2 Canada     
  15.2.3 Mexico     
 15.3 Europe      
  15.3.1 Germany     
  15.3.2 UK     
  15.3.3 Italy     
  15.3.4 France     
  15.3.5 Spain     
  15.3.6 Rest of Europe     
 15.4 Asia Pacific      
  15.4.1 Japan     
  15.4.2 China     
  15.4.3 India     
  15.4.4 Australia     
  15.4.5 New Zealand     
  15.4.6 South Korea     
  15.4.7 Rest of Asia Pacific     
 15.5 South America      
  15.5.1 Argentina     
  15.5.2 Brazil     
  15.5.3 Chile     
  15.5.4 Rest of South America     
 15.6 Middle East & Africa      
  15.6.1 Saudi Arabia     
  15.6.2 UAE     
  15.6.3 Qatar     
  15.6.4 South Africa     
  15.6.5 Rest of Middle East & Africa     
        
16 Key Developments       
 16.1 Agreements, Partnerships, Collaborations and Joint Ventures      
 16.2 Acquisitions & Mergers      
 16.3 New Product Launch      
 16.4 Expansions      
 16.5 Other Key Strategies      
        
17 Company Profiling        
 17.1 Bayer AG      
 17.2 Abbott Healthcare      
 17.3 Merck & Co.      
 17.4 Pfizer, Inc.      
 17.5 Novartis AG      
 17.6 Valeant Pharmaceuticals, Inc.      
 17.7 Johnson & Johnson      
 17.8 Allergan Plc      
 17.9 Santen Pharmaceutical Co. Ltd.      
 17.10 Genentech, Inc.      
 17.11 F. Hoffmann-La Roche Ltd      
 17.12 Regeneron Pharmaceuticals Inc.      
 17.13 Aerie Pharmaceuticals Inc.      
 17.14 Bausch Health Companies Inc.      
 17.15 Carl-Zeiss AG      
 17.16 Hoya Corporation      


List of Tables        
1 Global Ophthalmic Drugs Market Outlook, By Region (2019-2028) ($MN)       
2 Global Ophthalmic Drugs Market Outlook, By Type (2019-2028) ($MN)       
3 Global Ophthalmic Drugs Market Outlook, By Over-the-Counter Drugs (2019-2028) ($MN)       
4 Global Ophthalmic Drugs Market Outlook, By Prescription Drugs (2019-2028) ($MN)       
5 Global Ophthalmic Drugs Market Outlook, By Technology (2019-2028) ($MN)       
6 Global Ophthalmic Drugs Market Outlook, By Drug Delivery (2019-2028) ($MN)       
7 Global Ophthalmic Drugs Market Outlook, By Gene Therapy (2019-2028) ($MN)       
8 Global Ophthalmic Drugs Market Outlook, By Biologics (2019-2028) ($MN)       
9 Global Ophthalmic Drugs Market Outlook, By Small Molecule (2019-2028) ($MN)       
10 Global Ophthalmic Drugs Market Outlook, By Cell Therapy (2019-2028) ($MN)       
11 Global Ophthalmic Drugs Market Outlook, By Drug Variation (2019-2028) ($MN)       
12 Global Ophthalmic Drugs Market Outlook, By Generic Drugs (2019-2028) ($MN)       
13 Global Ophthalmic Drugs Market Outlook, By Branded Drugs (2019-2028) ($MN)       
14 Global Ophthalmic Drugs Market Outlook, By Indication (2019-2028) ($MN)       
15 Global Ophthalmic Drugs Market Outlook, By Glaucoma (2019-2028) ($MN)       
16 Global Ophthalmic Drugs Market Outlook, By Dry Eye (2019-2028) ($MN)       
17 Global Ophthalmic Drugs Market Outlook, By Cataract (2019-2028) ($MN)       
18 Global Ophthalmic Drugs Market Outlook, By Retinal Disorders (2019-2028) ($MN)       
19 Global Ophthalmic Drugs Market Outlook, By Diabetic Retinopathy (2019-2028) ($MN)       
20 Global Ophthalmic Drugs Market Outlook, By Macular Degeneration (2019-2028) ($MN)       
21 Global Ophthalmic Drugs Market Outlook, By Uveitis (2019-2028) ($MN)       
22 Global Ophthalmic Drugs Market Outlook, By Eye Infection/Inflammation/Eye Allergy (2019-2028) ($MN)       
23 Global Ophthalmic Drugs Market Outlook, By Allergic Conjunctivitis (2019-2028) ($MN)       
24 Global Ophthalmic Drugs Market Outlook, By Age-Related Macular Degeneration (AMD) (2019-2028) ($MN)       
25 Global Ophthalmic Drugs Market Outlook, By Diabetic Eye Disease (2019-2028) ($MN)       
26 Global Ophthalmic Drugs Market Outlook, By Other Indications (2019-2028) ($MN)       
27 Global Ophthalmic Drugs Market Outlook, By Eyelash Hypotrichosis (2019-2028) ($MN)       
28 Global Ophthalmic Drugs Market Outlook, By Optic Neuropathy (2019-2028) ($MN)       
29 Global Ophthalmic Drugs Market Outlook, By Distribution Channel (2019-2028) ($MN)       
30 Global Ophthalmic Drugs Market Outlook, By Drug Stores (2019-2028) ($MN)       
31 Global Ophthalmic Drugs Market Outlook, By Hospital Pharmacies (2019-2028) ($MN)       
32 Global Ophthalmic Drugs Market Outlook, By Online Pharmacies (2019-2028) ($MN)       
33 Global Ophthalmic Drugs Market Outlook, By Eye Health Clinics (2019-2028) ($MN)       
34 Global Ophthalmic Drugs Market Outlook, By Retail Pharmacies/Independent Pharmacies (2019-2028) ($MN)       
35 Global Ophthalmic Drugs Market Outlook, By Route of Administration (2019-2028) ($MN)       
36 Global Ophthalmic Drugs Market Outlook, By Systemic (2019-2028) ($MN)       
37 Global Ophthalmic Drugs Market Outlook, By Local Ocular (2019-2028) ($MN)       
38 Global Ophthalmic Drugs Market Outlook, By Retrobulbar (2019-2028) ($MN)       
39 Global Ophthalmic Drugs Market Outlook, By Subconjunctival (2019-2028) ($MN)       
40 Global Ophthalmic Drugs Market Outlook, By Intracameral (2019-2028) ($MN)       
41 Global Ophthalmic Drugs Market Outlook, By Intravitreal (2019-2028) ($MN)       
42 Global Ophthalmic Drugs Market Outlook, By Topical (2019-2028) ($MN)       
43 Global Ophthalmic Drugs Market Outlook, By Oral (2019-2028) ($MN)        
44 Global Ophthalmic Drugs Market Outlook, By Parenteral (2019-2028) ($MN)       
45 Global Ophthalmic Drugs Market Outlook, By Dosage Form (2019-2028) ($MN)       
46 Global Ophthalmic Drugs Market Outlook, By Solid Ophthalmic Drug Forms (2019-2028) ($MN)       
47 Global Ophthalmic Drugs Market Outlook, By Liquid Ophthalmic Drug Forms (2019-2028) ($MN)       
48 Global Ophthalmic Drugs Market Outlook, By Multicompartment Drug Delivery Systems (2019-2028) ($MN)       
49 Global Ophthalmic Drugs Market Outlook, By Semisolid Ophthalmic Drug Forms (2019-2028) ($MN)       
50 Global Ophthalmic Drugs Market Outlook, By Delivery Type (2019-2028) ($MN)       
51 Global Ophthalmic Drugs Market Outlook, By Eye Solutions (2019-2028) ($MN)       
52 Global Ophthalmic Drugs Market Outlook, By Capsules & Tablets (2019-2028) ($MN)       
53 Global Ophthalmic Drugs Market Outlook, By Eye Ointment (2019-2028) ($MN)       
54 Global Ophthalmic Drugs Market Outlook, By Gels (2019-2028) ($MN)       
55 Global Ophthalmic Drugs Market Outlook, By Eye Drops (2019-2028) ($MN)       
56 Global Ophthalmic Drugs Market Outlook, By Therapeutic Class (2019-2028) ($MN)       
57 Global Ophthalmic Drugs Market Outlook, By Anti-Inflammatory (2019-2028) ($MN)       
58 Global Ophthalmic Drugs Market Outlook, By Steroidal Drugs (2019-2028) ($MN)       
59 Global Ophthalmic Drugs Market Outlook, By Non-Steroidal Anti-Inflammatory drugs (NSAIDs) (2019-2028) ($MN)       
60 Global Ophthalmic Drugs Market Outlook, By Antibiotics (2019-2028) ($MN)       
61 Global Ophthalmic Drugs Market Outlook, By Anti-Allergy (2019-2028) ($MN)       
62 Global Ophthalmic Drugs Market Outlook, By Anti-Glaucoma Drugs (2019-2028) ($MN)       
63 Global Ophthalmic Drugs Market Outlook, By Prostaglandin Analogs (2019-2028) ($MN)       
64 Global Ophthalmic Drugs Market Outlook, By Combined Medication (2019-2028) ($MN)       
65 Global Ophthalmic Drugs Market Outlook, By Alpha Agonist (2019-2028) ($MN)       
66 Global Ophthalmic Drugs Market Outlook, By Beta-Blockers (2019-2028) ($MN)       
67 Global Ophthalmic Drugs Market Outlook, By Anti-Angiogenic (2019-2028) ($MN)       
68 Global Ophthalmic Drugs Market Outlook, By Anti-Infective Drugs (2019-2028) ($MN)       
69 Global Ophthalmic Drugs Market Outlook, By Anti-Fungal Drugs (2019-2028) ($MN)       
70 Global Ophthalmic Drugs Market Outlook, By Anti-Bacterial Drugs (2019-2028) ($MN)       
71 Global Ophthalmic Drugs Market Outlook, By Anti-Viral Drugs (2019-2028) ($MN)       
72 Global Ophthalmic Drugs Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) Agents (2019-2028) ($MN)       
73 Global Ophthalmic Drugs Market Outlook, By Retinal Drug (2019-2028) ($MN)       
74 Global Ophthalmic Drugs Market Outlook, By Other Therapeutic Classes (Cyclosporine) (2019-2028) ($MN)       
75 Global Ophthalmic Drugs Market Outlook, By End User (2019-2028) ($MN)       
76 Global Ophthalmic Drugs Market Outlook, By Specialty Clinics (2019-2028) ($MN)       
77 Global Ophthalmic Drugs Market Outlook, By Hospitals (2019-2028) ($MN)       
78 Global Ophthalmic Drugs Market Outlook, By Pharmacy (2019-2028) ($MN)       
        
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials